Phenotypic screens targeting neurodegenerative diseases

Journal of Biomolecular Screening

Volumn 19, Issue 1, 2014, Pages 1-16

  Zhang, Minhua ^a   Luo, Guangrui ^a   Zhou, Yanjiao ^a   Wang, Shaohui ^a   Zhong, Zhong ^a  

^a GLAXOSMITHKLINE   (China)

Author keywords

neurodegenerative diseases; phenotypic screening; technical considerations

Indexed keywords

ALPHA SYNUCLEIN; BENALFOCIN; BROXURIDINE; HUNTINGTIN; IMATINIB; QUINAZOLINE; VORINOSTAT;

CELL VIABILITY; CYTOTOXICITY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG SCREENING; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NERVE FIBER REGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SPINAL MUSCULAR ATROPHY; SUBSTANTIA NIGRA;

NEURODEGENERATIVE DISEASES; PHENOTYPIC SCREENING; TECHNICAL CONSIDERATIONS;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; NEURODEGENERATIVE DISEASES; PHENOTYPE;

EID: 84890832843     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113499777     Document Type: Review

References (104)

1. Fearnley J. M., Lees A. J.. Ageing and Parkinson's Disease: Substantia Nigra Regional Selectivity. Brain. 1991 ; 114: 2283-2301
2. Schliebs R., Arendt T.. The Cholinergic System in Aging and Neuronal Degeneration. Behav. Brain Res. 2011 ; 221: 555-563
3. A Novel Gene Containing a Trinucleotide Repeat That Is Expanded and Unstable on Huntington's Disease Chromosomes. Cell. 1993 ; 72: 971-983
4. Lesage S., Brice A.. Role of Mendelian Genes in "Sporadic" Parkinson's Disease. Parkinsonism Relat. Disord. 2012 ; 18: S66 - S70
5. Schellenberg G. D., Montine T. J.. The Genetics and Neuropathology of Alzheimer's Disease. Acta Neuropathol. 2012 ; 124: 305-323
6. Atri A.. Effective Pharmacological Management of Alzheimer's Disease. Am. J. Manag. Care. 2011 ; 17: S346 - S355
7. Del S. F., Albanese A.. Levodopa-Induced Dyskinesias and Their Management. J. Neurol. 2008 ; 255: 32-41
8. Corbett A., Ballard C.. New and Emerging Treatments for Alzheimer's Disease. Expert. Opin. Emerg. Drugs. 2012 ; 17: 147-156
9. Meissner W. G., Frasier M., Gasser T., et al. Priorities in Parkinson's Disease Research. Nat. Rev. Drug Discov. 2011 ; 10: 377-393
10. Rosamond J., Allsop A.. Harnessing the Power of the Genome in the Search for New Antibiotics. Science. 2000 ; 287: 1973-1976
11. Swinney D. C., Anthony J.. How Were New Medicines Discovered?. Nat. Rev. Drug Discov. 2011 ; 10: 507-519
12. Awouters F. H., Lewi P. J.. Forty Years of Antipsychotic Drug Research - From Haloperidol to Paliperidone - with Dr. Paul Janssen. Arzneimittelforschung. 2007 ; 57: 625-632
13. Goodfellow P. N.. Genomics and Drugs: An Interview Conducted by Holger Breithaupt and Caroline Hadley. EMBO Rep. 2004 ; 5: 843-846
14. Burbaum J. J., Sigal N. H.. New Technologies for High-Throughput Screening. Curr. Opin. Chem. Biol. 1997 ; 1: 72-78
15. Rinne J. O., Brooks D. J., Rossor M. N., et al. 11C-PiB PET Assessment of Change in Fibrillar Amyloid-Beta Load in Patients with Alzheimer's Disease Treated with Bapineuzumab: A Phase 2, Double-Blind, Placebo-Controlled, Ascending-Dose Study. Lancet Neurol. 2010 ; 9: 363-372
16. Berkrot B. Pfizer, J&J Scrap Alzheimer's Studies as Drug Fails. August7, 2012. http://www.reuters.com/article/2012/08/07/us-pfizer-alzheimers- idUSBRE8751F120120807.
17. Grundman M., Dibernardo A., Raghavan N., et al. A Watershed Year for Alzheimer's Disease Research. J. Nutr. Health Aging. 2012 2013 ; 17: 51-53
18. Brodie M. J.. Antiepileptic Drug Therapy: The Story So Far. Seizure. 2010 ; 19: 650-655
19. Pruss R. M.. Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms. CNS Neurol. Disord. Drug Targets. 2010 ; 9: 693-700
20. Alberio T., Lopiano L., Fasano M.. Cellular Models to Investigate Biochemical Pathways in Parkinson's Disease. FEBS J. 2012 ; 279: 1146-1155
21. Titus S. A., Southall N., Marugan J., et al. High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington's Disease Model. Curr. Chem. Genom. 2012 ; 6: 79-86
22. Chakrabarti E., Smith J. D.. Drug Library Screen to Identify Compounds That Decrease Secreted Abeta from a Human Cell Line. Curr. Alzheimer Res. 2005 ; 2: 255-259
23. Jones J. R., Lebar M. D., Jinwal U. K., et al. The Diarylheptanoid (+)-aR,11S-myricanol and Two Flavones from Bayberry (Myrica cerifera) Destabilize the Microtubule-Associated Protein tau. J. Nat. Prod. 2011 ; 74: 38-44
24. Ross N. T., Metkar S. R., Le H., et al. Identification of a Small Molecule That Selectively Inhibits Alpha-Synuclein Translational Expression. Probe Reports from the NIH Molecular Libraries Program. 2011 ;:
25. Barber S. C., Higginbottom A., Mead R. J., et al. An In Vitro Screening Cascade to Identify Neuroprotective Antioxidants in ALS. Free Radic. Biol. Med. 2009 ; 46: 1127-1138
26. Ock J., Suk K.. Anti-inflammatory Effects of Synthetic Compound KT-14480 in Lipopolysaccharide-Stimulated Microglia Cells. J. Pharm. Pharmacol. 2010 ; 62: 279-285
27. Cisbani G., Cicchetti F.. An In Vitro Perspective on the Molecular Mechanisms Underlying Mutant huntingtin Protein Toxicity. Cell Death. Dis. 2012 ; 3: e382
28. DiFiglia M., Sapp E., Chase K. O., et al. Aggregation of huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain. Science. 1997 ; 277: 1990-1993
29. Ross C. A., Poirier M. A.. Protein Aggregation and Neurodegenerative Disease. Nat. Med. 2004 ; 10: S10 - S17
30. Hyman B. T., Trojanowski J. Q.. Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. J. Neuropathol. Exp. Neurol. 1997 ; 56: 1095-1097
31. Selkoe D. J.. Alzheimer's Disease Is a Synaptic Failure. Science. 2002 ; 298: 789-791
32. Grober E., Dickson D., Sliwinski M. J., et al. Memory and Mental Status Correlates of Modified Braak Staging. Neurobiol. Aging. 1999 ; 20: 573-579
33. Braak H., Del T. K., Rub U., et al. Staging of Brain Pathology Related to Sporadic Parkinson's Disease. Neurobiol. Aging. 2003 ; 24: 197-211
34. Burre J., Sharma M., Sudhof T. C.. Systematic Mutagenesis of Alpha-Synuclein Reveals Distinct Sequence Requirements for Physiological and Pathological Activities. J. Neurosci. 2012 ; 32: 15227-15242
35. Volpicelli-Daley L. A., Luk K. C., Patel T. P., et al. Exogenous Alpha-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death. Neuron. 2011 ; 72: 57-71
36. Radak Z., Zhao Z., Goto S., et al. Age-Associated Neurodegeneration and Oxidative Damage to Lipids, Proteins and DNA. Mol. Aspects Med. 2011 ; 32: 305-315
37. Nunomura A., Perry G., Aliev G., et al. Oxidative Damage Is the Earliest Event in Alzheimer Disease. J. Neuropathol. Exp. Neurol. 2001 ; 60: 759-767
38. Hirsch E. C., Hunot S.. Neuroinflammation in Parkinson's Disease: A Target for Neuroprotection?. Lancet Neurol. 2009 ; 8: 382-397
39. Seyb K. I., Schuman E. R., Ni J., et al. Identification of Small Molecule Inhibitors of Beta-Amyloid Cytotoxicity through a Cell-Based High-Throughput Screening Platform. J. Biomol. Screen. 2008 ; 13: 870-878
40. Zhao D. L., Zou L. B., Zhou L. F., et al. A Cell-Based Model of Alpha-Synucleinopathy for Screening Compounds with Therapeutic Potential of Parkinson's Disease. Acta Pharmacol. Sin. 2007 ; 28: 616-626
41. Yoon I. S., Au Q., Barber J. R., et al. Development of a High-Throughput Screening Assay for Cytoprotective Agents in Rotenone-Induced Cell Death. Anal. Biochem. 2010 ; 407: 205-210
42. Griffioen G., Duhamel H., Van D. N., et al. A Yeast-Based Model of Alpha-Synucleinopathy Identifies Compounds with Therapeutic Potential. Biochim. Biophys. Acta. 2006 ; 1762: 312-318
43. Su L. J., Auluck P. K., Outeiro T. F., et al. Compounds from an Unbiased Chemical Screen Reverse Both ER-to-Golgi Trafficking Defects and Mitochondrial Dysfunction in Parkinson's Disease Models. Dis. Model. Mech. 2010 ; 3: 194-208
44. Schmidt F., Champy P., Seon-Meniel B., et al. Chemicals Possessing a Neurotrophin-like Activity on Dopaminergic Neurons in Primary Culture. PLoS One. 2009 ; 4: e6215
45. Braungart E., Gerlach M., Riederer P., et al. Caenorhabditis elegans MPP+ Model of Parkinson's Disease for High-Throughput Drug Screenings. Neurodegener. Dis. 2004 ; 1: 175-183
46. Usher L. C., Johnstone A., Erturk A., et al. A Chemical Screen Identifies Novel Compounds That Overcome Glial-Mediated Inhibition of Neuronal Regeneration. J. Neurosci. 2010 ; 30: 4693-4706
47. Xu X., Lei Y., Luo J., et al. Prevention of Beta-Amyloid Induced Toxicity in Human iPS Cell-Derived Neurons by Inhibition of Cyclin-Dependent Kinases and Associated Cell Cycle Events. Stem Cell Res. 2013 ; 10: 213-227
48. Hoing S., Rudhard Y., Reinhardt P., et al. Discovery of Inhibitors of Microglial Neurotoxicity Acting through Multiple Mechanisms Using a Stem-Cell-Based Phenotypic Assay. Cell Stem Cell. 2012 ; 11: 620-632
49. McKinley E. T., Baranowski T. C., Blavo D. O., et al. Neuroprotection of MPTP-Induced Toxicity in Zebrafish Dopaminergic Neurons. Brain Res. Mol. Brain Res. 2005 ; 141: 128-137
50. Diniz B. S., Teixeira A. L.. Brain-Derived Neurotrophic Factor and Alzheimer's Disease: Physiopathology and Beyond. Neuromolecular. Med. 2011 ; 13: 217-222
51. Evans J. R., Barker R. A.. Neurotrophic Factors as a Therapeutic Target for Parkinson's Disease. Expert. Opin. Ther. Targets. 2008 ; 12: 437-447
52. Zhang H., Jarjour A. A., Boyd A., et al. Central Nervous System Remyelination in Culture - A Tool for Multiple Sclerosis Research. Exp. Neurol. 2011 ; 230: 138-148
53. Lindvall O., Kokaia Z., Martinez-Serrano A.. Stem Cell Therapy for Human Neurodegenerative Disorders: How to Make It Work. Nat. Med. 2004 ; 10: S42 - S50
54. Aboody K., Capela A., Niazi N., et al. Translating Stem Cell Studies to the Clinic for CNS Repair: Current State of the Art and the Need for a Rosetta Stone. Neuron. 2011 ; 70: 597-613
55. Ming G. L., Song H.. Adult Neurogenesis in the Mammalian Central Nervous System. Annu. Rev. Neurosci. 2005 ; 28: 223-250
56. Saxe J. P., Wu H., Kelly T. K., et al. A Phenotypic Small-Molecule Screen Identifies an Orphan Ligand-Receptor Pair That Regulates Neural Stem Cell Differentiation. Chem. Biol. 2007 ; 14: 1019-1030
57. Kim K. J., Wang J., Xu X., et al. A Chemical Genomics Screen to Discover Genes That Modulate Neural Stem Cell Differentiation. J. Biomol. Screen. 2012 ; 17: 129-139
58. Warashina M., Min K. H., Kuwabara T., et al. A Synthetic Small Molecule That Induces Neuronal Differentiation of Adult Hippocampal Neural Progenitor Cells. Angew. Chem. Int. Ed Engl. 2006 ; 45: 591-593
59. Wurdak H., Zhu S., Min K. H., et al. A Small Molecule Accelerates Neuronal Differentiation in the Adult Rat. Proc. Natl. Acad. Sci. U. S. A. 2010 ; 107: 16542-16547
60. Zhao W. N., Cheng C., Theriault K. M., et al. A High-Throughput Screen for Wnt/beta-Catenin Signaling Pathway Modulators in Human iPSC-Derived Neural Progenitors. J. Biomol. Screen. 2012 ; 17: 1252-1263
61. Pieper A. A., Xie S., Capota E., et al. Discovery of a Proneurogenic, Neuroprotective Chemical. Cell. 2010 ; 142: 39-51
62. Namdaran P., Reinhart K. E., Owens K. N., et al. Identification of Modulators of Hair Cell Regeneration in the Zebrafish Lateral Line. J. Neurosci. 2012 ; 32: 3516-3528
63. Buckley C. E., Marguerie A., Roach A. G., et al. Drug Reprofiling Using Zebrafish Identifies Novel Compounds with Potential Pro-myelination Effects. Neuropharmacology. 2010 ; 59: 149-159
64. Lee G., Ramirez C. N., Kim H., et al. Large-Scale Screening Using Familial Dysautonomia Induced Pluripotent Stem Cells Identifies Compounds That Rescue IKBKAP Expression. Nat. Biotechnol. 2012 ; 30: 1244-1248
65. Lipinski C. A., Lombardo F., Dominy B. W., et al. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv. Drug Deliv. Rev. 2001 ; 46: 3-26
66. Walters W. P.. Going further Than Lipinski's Rule in Drug Design. Expert. Opin. Drug Discov. 2012 ; 7: 99-107
67. Leeson P. D., St-Gallay S. A.. The Influence of the "Organizational Factor" on Compound Quality in Drug Discovery. Nat. Rev. Drug Discov. 2011 ; 10: 749-765
68. Keseru G. M., Makara G. M.. The Influence of Lead Discovery Strategies on the Properties of Drug Candidates. Nat. Rev. Drug Discov. 2009 ; 8: 203-212
69. Irwin J. J., Shoichet B. K.. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening. J. Chem. Inf. Model. 2005 ; 45: 177-182
70. Huang R., Southall N., Wang Y., et al. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics. Sci. Transl. Med. 2011 ; 3 :
71. Nolan G. P.. What's Wrong with Drug Screening Today. Nat. Chem. Biol. 2007 ; 3: 187-191
72. Thompson P. M., Vinters H. V.. Pathologic Lesions in Neurodegenerative Diseases. Prog. Mol. Biol. Transl. Sci. 2012 ; 107: 1-40
73. Forno L. S.. Neuropathology of Parkinson's Disease. J. Neuropathol. Exp. Neurol. 1996 ; 55: 259-272
74. Ebert A. D., Yu J., Rose F. F., et al. Induced Pluripotent Stem Cells from a Spinal Muscular Atrophy Patient. Nature. 2009 ; 457: 277-280
75. Israel M. A., Yuan S. H., Bardy C., et al. Probing Sporadic and Familial Alzheimer's Disease Using Induced Pluripotent Stem Cells. Nature. 2012 ; 482: 216-220
76. Nguyen H. N., Byers B., Cord B., et al. LRRK2 Mutant iPSC-derived DA Neurons Demonstrate Increased Susceptibility to Oxidative Stress. Cell Stem Cell. 2011 ; 8: 267-280
77. Xu X. H., Zhong Z.. Disease Modeling and Drug Screening for Neurological Diseases Using Human Induced Pluripotent Stem Cells. Acta Pharmacol. Sin. 2013 ; 34: 755-764
78. Cottet-Rousselle C., Ronot X., Leverve X., et al. Cytometric Assessment of Mitochondria Using Fluorescent Probes. Cytometry A. 2011 ; 79: 405-425
79. Chen X., Tian X., Shin I., et al. Fluorescent and Luminescent Probes for Detection of Reactive Oxygen and Nitrogen Species. Chem. Soc. Rev. 2011 ; 40: 4783-4804
80. Fennell M., Chan H., Wood A.. Multiparameter Measurement of Caspase 3 Activation and Apoptotic Cell Death in NT2 Neuronal Precursor Cells Using High-Content Analysis. J. Biomol. Screen. 2006 ; 11: 296-302
81. Thyagarajan B., Liu Y., Shin S., et al. Creation of Engineered Human Embryonic Stem Cell Lines Using phiC31 Integrase. Stem Cells. 2008 ; 26: 119-126
82. Ye L., Chang J. C., Lin C., et al. Generation of Induced Pluripotent Stem Cells Using Site-Specific Integration with Phage Integrase. Proc. Natl. Acad. Sci. U. S. A. 2010 ; 107: 19467-19472
83. Kaltenbach L. S., Bolton M. M., Shah B., et al. Composite Primary Neuronal High-Content Screening Assay for Huntington's Disease Incorporating Non-cell-autonomous Interactions. J. Biomol. Screen. 2010 ; 15: 806-819
84. Nguyen L., Wright S., Lee M., et al. Quantifying Amyloid Beta (Abeta)-Mediated Changes in Neuronal Morphology in Primary Cultures: Implications for Phenotypic Screening. J. Biomol. Screen. 2012 ; 17: 835-842
85. Gasparri F.. An Overview of Cell Phenotypes in HCS: Limitations and Advantages. Expert. Opin. Drug Discov. 2009 ; 4: 643-657
86. Ekins S., Williams A. J.. Finding Promiscuous Old Drugs for New Uses. Pharm. Res. 2011 ; 28: 1785-1791
87. Andersson O., Adams B. A., Yoo D., et al. Adenosine Signaling Promotes Regeneration of Pancreatic Beta Cells In Vivo. Cell Metab. 2012 ; 15: 885-894
88. Terstappen G. C., Schlupen C., Raggiaschi R., et al. Target Deconvolution Strategies in Drug Discovery. Nat. Rev. Drug Discov. 2007 ; 6: 891-903
89. Bantscheff M., Drewes G.. Chemoproteomic Approaches to Drug Target Identification and Drug Profiling. Bioorg. Med. Chem. 2012 ; 20: 1973-1978
90. Cong F., Cheung A. K., Huang S. M.. Chemical Genetics-Based Target Identification in Drug Discovery. Annu. Rev. Pharmacol. Toxicol. 2012 ; 52: 57-78
91. Ding S., Wu T. Y., Brinker A., et al. Synthetic Small Molecules That Control Stem Cell Fate. Proc. Natl. Acad. Sci. U. S. A. 2003 ; 100: 7632-7637
92. Jarecki J., Chen X., Bernardino A., et al. Diverse Small-Molecule Modulators of SMN Expression Found by High-Throughput Compound Screening: Early Leads towards a Therapeutic for Spinal Muscular Atrophy. Hum. Mol. Genet. 2005 ; 14: 2003-2018
93. Singh J., Salcius M., Liu S. W., et al. DcpS as a Therapeutic Target for Spinal Muscular Atrophy. ACS Chem. Biol. 2008 ; 3: 711-722
94. Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program [press release].January3, 2013. http://www.repligen.com/sites/ default/files/news/pfizersmapartnershipfinal3jan12.pdf.
95. Ong S. E., Schenone M., Margolin A. A., et al. Identifying the Proteins to Which Small-Molecule Probes and Drugs Bind in Cells. Proc. Natl. Acad. Sci. U. S. A. 2009 ; 106: 4617-4622
96. Ong S. E., Li X., Schenone M., et al. Identifying Cellular Targets of Small-Molecule Probes and Drugs with Biochemical Enrichment and SILAC. Methods Mol. Biol. 2012 ; 803: 129-140
97. Ross P. L., Huang Y. N., Marchese J. N., et al. Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-Reactive Isobaric Tagging Reagents. Mol. Cell Proteomics. 2004 ; 3: 1154-1169
98. Bantscheff M., Eberhard D., Abraham Y., et al. Quantitative Chemical Proteomics Reveals Mechanisms of Action of Clinical ABL Kinase Inhibitors. Nat. Biotechnol. 2007 ; 25: 1035-1044
99. Lamb J., Crawford E. D., Peck D., et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. Science. 2006 ; 313: 1929-1935
100. Qu X. A., Rajpal D. K.. Applications of Connectivity Map in Drug Discovery and Development. Drug Discov. Today. 2012 ; 17: 1289-1298
101. Johnstone A. L., Reierson G. W., Smith R. P., et al. A Chemical Genetic Approach Identifies Piperazine Antipsychotics as Promoters of CNS Neurite Growth on Inhibitory Substrates. Mol. Cell Neurosci. 2012 ; 50: 125-135
102. Marks P. A.. Discovery and Development of SAHA as an Anticancer Agent. Oncogene. 2007 ; 26: 1351-1356
103. Richon V. M., Emiliani S., Verdin E., et al. A Class of Hybrid Polar Inducers of Transformed Cell Differentiation Inhibits Histone Deacetylases. Proc. Natl. Acad. Sci. U. S. A. 1998 ; 95: 3003-3007
104. Minucci S., Pelicci P. G.. Histone Deacetylase Inhibitors and the Promise of Epigenetic (and More) Treatments for Cancer. Nat. Rev. Cancer. 2006 ; 6: 38-51